全文获取类型
收费全文 | 9671篇 |
免费 | 750篇 |
国内免费 | 125篇 |
专业分类
耳鼻咽喉 | 106篇 |
儿科学 | 119篇 |
妇产科学 | 319篇 |
基础医学 | 643篇 |
口腔科学 | 360篇 |
临床医学 | 1186篇 |
内科学 | 1936篇 |
皮肤病学 | 119篇 |
神经病学 | 259篇 |
特种医学 | 387篇 |
外国民族医学 | 1篇 |
外科学 | 2065篇 |
综合类 | 785篇 |
预防医学 | 1310篇 |
眼科学 | 218篇 |
药学 | 523篇 |
中国医学 | 61篇 |
肿瘤学 | 149篇 |
出版年
2024年 | 13篇 |
2023年 | 177篇 |
2022年 | 325篇 |
2021年 | 518篇 |
2020年 | 515篇 |
2019年 | 490篇 |
2018年 | 490篇 |
2017年 | 392篇 |
2016年 | 378篇 |
2015年 | 379篇 |
2014年 | 833篇 |
2013年 | 799篇 |
2012年 | 489篇 |
2011年 | 591篇 |
2010年 | 494篇 |
2009年 | 450篇 |
2008年 | 423篇 |
2007年 | 400篇 |
2006年 | 352篇 |
2005年 | 288篇 |
2004年 | 292篇 |
2003年 | 233篇 |
2002年 | 169篇 |
2001年 | 124篇 |
2000年 | 127篇 |
1999年 | 96篇 |
1998年 | 77篇 |
1997年 | 71篇 |
1996年 | 75篇 |
1995年 | 63篇 |
1994年 | 65篇 |
1993年 | 41篇 |
1992年 | 38篇 |
1991年 | 28篇 |
1990年 | 27篇 |
1989年 | 33篇 |
1988年 | 21篇 |
1987年 | 26篇 |
1986年 | 12篇 |
1985年 | 18篇 |
1984年 | 11篇 |
1983年 | 16篇 |
1982年 | 13篇 |
1981年 | 12篇 |
1980年 | 9篇 |
1979年 | 13篇 |
1978年 | 13篇 |
1976年 | 5篇 |
1973年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
一种四点弯曲单向交变应变细胞加载装置的研制 总被引:6,自引:0,他引:6
本文根据细胞动力学对力学因素的响应,设计研制了一种四点弯曲单向交变应变加载装置。通过对Wistar大鼠成骨细胞的试验,以及流式细胞仪(FCM)对细胞DNA分析检测的结果,表明研制是成功的,并可广泛使用于内皮细胞、成纤维细胞、平滑肌细胞、心肌细胞等组织工程和生物医学工程、人机工程学、细胞力学方面的研究。 相似文献
92.
93.
Sezai A Shiono M Orime Y Nakata K Hata M Iida M Kashiwazaki S Kinoshita J Nemoto M Koujima T Furuichi M Eda K Hirose H Yoshino T Saitoh A Taniguchi Y Sezai Y 《Artificial organs》1999,23(3):280-285
We examined a major organ function during 3 h biventricular assisted circulation after acute myocardial infarction model in the pig. In left ventricular circulation, the outflow cannula was placed in the ascending aorta and an inflow cannula through the mitral valve in the left ventricle. A pump (pulsatile group, Zeon Medical, Inc., Tokyo, Japan and nonpulsatile group, Nikkiso HPM-15, Nikkiso, Inc., Tokyo, Japan) was connected to each cannula. In right ventricular circulation, the outflow cannula was placed in the pulmonary artery and an inflow cannula in the right ventricle. The right ventricular circulation was supported by a nonpulsatile pump (Nikkiso HPM-15). The items measured were the regional blood flows of the cortex and medulla in the kidney, white matter and gray mater in brain, and liver; renal arterial flow; carotid arterial flow; portal vein flow; common hepatic arterial flow; arterial ketone body ratio (AKBR); and lactate/pyrubic acid (L/P). In the pulsatile group, the renal cortical blood flow increased, and the medulla blood flow decreased. On the other hand, in the nonpulsatile group, both regional blood flows decreased. That means that in the pulsatile assisted group intrarenal redistribution improved rather than in the nonpulsatile assisted group. In addition the liver regional blood flow, AKBR, and L/P showed significant differences between the pulsatile and nonpulsatile groups. On the other hand, the white matter and gray matter regional blood flows and carotid arterial flow did not show significant differences between the groups. The results of our study indicated that pulsatile circulation produced superior circulation in the kidney and liver, and microcirculation on the cell level was superior as well in early treatment of acute heart failure. 相似文献
94.
An ultracompact, completely implantable permanent use electromechanical ventricular assist device (VAD) and total artificial heart (TAH) intended for 50-60 kg size patients have been developed. The TAH and VAD share a miniature electromechanical actuator that comprises a DC brushless motor and a planetary roller screw. The rotational force of the motor is converted into the rectilinear force of the roller screw to actuate the blood pump. The TAH is a one piece design with left and right pusher plate type blood pumps sandwiching an electromechanical actuator. The VAD is one half of the TAH with the same actuator but a different pump housing and a backplate. The blood contacting surfaces, including those of the flexing diaphragm and pump housing, of both the VAD and TAH were made of biocompatible polyurethane. The diameter, thickness, volume, and weight of the VAD are 90 mm, 56 mm, 285 cc, and 380 g, respectively, while those of the TAH are 90 mm, 73 mm, 400 cc, and 440 g, respectively. The design stroke volume of both the VAD and TAH is 60 cc with the stroke length being 12 mm. The stroke length and motor speed are controlled solely based on the commutation signals of the motor. An in vitro study revealed that a maximum pump flow of 7.5 L/min can be obtained with a pump rate of 140 bpm against a mean afterload of 100 mm Hg. The power requirement ranged from 4 to 6 W to deliver a 4-5 L/min flow against a 100 mm Hg afterload with the electrical-to-hydraulic efficiency being 19-20%. Our VAD and TAH are the smallest of the currently available devices and suitable for bridge to transplant application as well as for permanent circulatory support of 50-60 kg size patients. 相似文献
95.
In a follow-up study 27 patients were evaluated after anterior cruciate ligament (ACL-)reconstruction combined with high tibial osteotomy because of chronic rupture of the ACL, cartilaginous lesions of the medial compartment and varus malalignment. They were divided into two groups. In 14 patients (non-LAD group) ACL reconstruction was performed using the central third of the autologous patellar tendon modified according to Eriksson-Trillat. Thirteen patients (LAD group) underwent repair with the same technique, but a Kennedy ligament augmentation device (LAD) in hot dog technique and fixed over the top was added. The postoperative treatment was the same in both groups. All patients were examined according to IKDC criteria. KT-1000 arthrometer testing at maximum manual traction was performed. Although the mean follow-up interval was more than double in the non-LAD group (non-LAD: 127 months vs LAD: 58 months), the subjective and clinical results, IKDC evaluation and KT-1000 arthrometer testing results were similar, showing no statistically significant difference. Further, no complications due to the use of LAD occurred. In this study no evident functional or clinical advantage from the augmentation performed could be shown.Investigation performed at the Department of Orthopaedic and Trauma Surgery, University Hospital Basle, Switzerland. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. Funds were received in total or partial support of the research or clinical study presented in this article. The funding sources were SUVA Assurance, Lucerne, and the science fund of the University Hospital Basle 相似文献
96.
John C. Norman Clifford C. Dacso George J. Reul Edward K. Massin Tomas Klima Barry D. Kahan John T. Reiser Denton A. Cooley 《Artificial organs》1978,2(4):413-420
The abdominal left ventricular assist device (ALVAD) is an order of magnitude more effective than conventional intra-aortic balloon pumping (IABP) in unloading and providing circulatory support to the failing left ventricle. This is a report of a unique case which demonstrates that in the absence of pulmonary vascular obstruction or constriction, the ALVAD can substitute for both left and right heart function. A 21-year-old patient with a congenital bicuspid aortic valve developed acute valvular endocarditis which rapidly progressed to congestive heart failure. An operation was undertaken, the mitral and aortic valves were excised and replaced by porcine heterografts, and a fistula from the right sinus of Valsalva to the right ventricle was closed. When coronary circulation was restored, irreversible ischemic contracture of the left ventricle, or "stone heart" syndrome, developed and emergency ALVAD or partial artificial heart implantation was effected. This device functioned as a total artificial heart for nearly six days, while a donor heart was sought. The patient then underwent removal of the ALVAD and cardiac and renal allografting. The transplanted heart functioned well, but the patient expired fifteen days later from gram-negative sepsis. 相似文献
97.
A new baby-spacer device for aerosolized bronchodilator administration in infants with bronchopulmonary disease 总被引:1,自引:0,他引:1
R. Kraemer P. Birrer K. Modelska C. Casaulta Aebischer M. H. Schöni 《European journal of pediatrics》1992,151(1):57-60
The response of salbutamol (Ventolin, Glaxo), topically administered from a metered dose inhaler (MDI) through a new baby-spacer-device (Babyhaler, Glaxo) was studied in 14 infants (8 wheezy infants, 3 infants with cystic fibrosis and 3 infants after respiratory distress syndrome), age 2.9–18.8 months. Changes in thoracic gas volume (TGV) as an estimate of pulmonary hyperinflation and changes in airway conductance (Gaw) as an estimate of bronchial obstruction were assessed by whole-body plethysmography. After baseline measurements, 1 puff of 100 g salbutamol was given repeatedly at 5 min intervals until 600 g have been inhaled and TGV and Gaw were measured after each inhalation at 5, 10, 15, 20, 25 and 30 min. Significant improvement in lung function was achieved in 57.1% of infants after 400 g and in 92.9% of infants after 600 g salbutamol. The study shows usefulness of bronchodilator treatment in infants with bronchopulmonary disease by a system with a MDI and baby-spacer-device. However a special dose-time relationship must be respected.Presented in part at the 1990 World Conference on Lung Health, May 20–24, 1990 — Boston, Massachusetts, U.S.A. 相似文献
98.
Noninvasive monitoring of rotary blood pumps: necessity, possibilities, and limitations 总被引:1,自引:0,他引:1
Schima H Trubel W Moritz A Wieselthaler G Stöhr HG Thoma H Losert U Wolner E 《Artificial organs》1992,16(2):195-202
Although rotary blood pumps do not contain an inherent mechanism for adaptation to physiological flow necessities, hitherto only a few efforts have been made to obtain robust monitoring and control methods. This paper discusses the necessity of noninvasive monitoring of such pumps and the crucial points of sensor selection and development. A strategy of monitoring atrial pressure out of the data obtained by the collapse of the atrial wall around the inflow cannula and initial results on animal tests and computer simulation of this method are discussed. This approach might lead to reliable and demand-responsive controllers, if some basic criteria are fulfilled. 相似文献
99.
A recent development in antithrombotic research allows the inhibition of platelet aggregation via protection of the glycoprotein IIb/IIIa receptor on the platelet membrane. We hypothesized that a GP IIb/IIIa receptor inhibitor would inhibit thromboxane-induced platelet aggregation during circulation in our in vitro ventricular assist device (VAD) circuit and preserve long-term platelet function. Twenty-one in vitro nonpulsatile centrifugal VAD circuits were simulated for 4 days using 450 ml of fresh human whole blood with or without glycoprotein IIb/IIIa receptor inhibitor (tirofiban). Platelet aggregation and degranulation were measured in whole blood induced by ristocetin, collagen, ADP, and thromboxane A2 (TXA2). The tirofiban-treated group preserved the platelet count and tended to exert these beneficial effects by inhibiting pathologic platelet aggregation induced by TXA2, collagen, and ADP as well as degranulation. Tirofiban may be useful in preserving platelet number and function during clinical VAD use. 相似文献
100.
Even though clinical acceptance of a nonpulsatile blood flow was demonstrated almost 45 years ago, the development of a nonpulsatile blood pump was completely ignored until 20 years ago. In 1979, the first author's group demonstrated that completely pulseless animals did not exhibit any abnormal physiology if 20% higher blood flows were provided to them. However, during the next 10 years (1979-1988), minimum efforts were provided for the development of a nonpulsatile, permanently implantable cardiac prosthesis. In 1989, the first author and his team at Baylor College of Medicine initiated a developmental strategy of various types of nonpulsatile rotary blood pumps, including a 2-day rotary blood pump for cardiopulmonary bypass application, a 2 week pump for ECMO and short-term circulatory assistance, a 2 year pump as a bridge to transplantation, and a permanently implantable cardiac prosthesis. Following the design and developmental strategy established in 1989, successful development of a 2-day pump (the Nikkiso-Fairway cardiopulmonary bypass pump) in 4 years (1989-1993), a 2 week pump (Kyocera gyro G1E3 pump) in 6 years (1992-1998), and a bridge to transplant pump (DeBakey LVAD-an axial flow blood pump) in 10 years (1988-1998) was made. Currently, a permanently implantable centrifugal blood pump development program is successfully completing its initial Phase 1 program of 5 years (1995-2000). Implantation exceeded 9 months without any negative findings. An additional 5 year Phase II program (2000-2005) is expected to complete such a device that will be clinically available. 相似文献